Safety and efficacy of transcatheter arterial embolization for management of refractory hematuria of prostatic origin

Epirubicin-loaded beads transarterial prostatic arterial chemoembolization is a promising treatment for advanced prostate cancer with lower urinary tract obstruction or hematuria—a case series report

“…(II) Recent hemostatic success in patients with hematuria was defined as no further active bleeding 1 month after the intervention or significantly reduced bleeding volume and no need for blood transfusions. Delayed recurrent bleeding was defined as the reappearance of active bleeding 1 month after the operation, requiring a blood transfusion, reintervention, or another interventional therapy (12). Short-term efficacy (PV as assessed by MRI, serum TPSA, IPSS score [to assess the relief of lower urinary tract symptoms), and QoL score] and adverse reactions (embolism syndrome, gastrointestinal reactions, impaired liver and kidney function, ectopic embolism, etc.)…”